|
Lotemax (Loteprednol Etabonate) Ophthalmic Suspension
|
|
Ophthalmic/Otic agent
|
|
Corticosteroid
|
|
To control inflammation following eye surgery, herpes of the eye, corneal injuries, seasonal Allergic Conjunctivitis
|
|
Adults: Allergic Conjunctivitis: 1-2 drops into affected eye(s) 4 times a day. Dose may be increased up to 1 drop every hour within the first week of therapy. Post-op: 1 to 2 drops into the operated eye(s) 4 times daily starting 24 hours following surgery and continue for the next 2 weeks.
|
|
Category C
|
|
Burning, itching eye, dry eye, runny nose, headache, blurring of vision, eye ball pain, nausea, vomiting, recurrent ocular herpetic infection
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
|
|
|